N@N

BURLINGTON, Mass.--([ BUSINESS WIRE ])--Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Burt Adelman, M.D. as Chief Medical Officer. Dr. Adelman will lead the development and regulatory strategy for the Companyas non-histamine-mediated angioedema franchise.

"I am excited to be working with the Dyax team, as we focus on developing a suite of products designed to identify and appropriately treat the tens of thousands of patients affected by non-histamine-mediated angioedemas."

Dr. Adelman has experience and expertise in drug development and commercialization. He led the successful development of a number of important biologic and small molecule therapeutics, including Angiomax, Avonex, Amevive and Tysabri. Dr. Adelman began his career with Biogen Idec (then Biogen) in 1991 as Director of Medical Research, and held positions of increasing responsibility including Vice President, Regulatory Affairs, Vice President, Development Operations, and Executive Vice President, Research and Development. He retired from Biogen Idec as Executive Vice President of Portfolio Strategy in 2007. Dr. Adelman serves as a lecturer in medicine at the Harvard Medical School, and was Associate Professor of Medicine at the Medical College of Virginia, and Chief of the Hematology-Oncology service at the Hunter Holmes McGuire VA Medical Center.

aBurt is a thought leader with an unparalleled record of success in developing and commercializing important therapeutics,a stated Gustav Christensen, President and Chief Executive Officer of Dyax. aHis scientific, clinical, regulatory and market-based expertise will be invaluable as we expand our KALBITOR-led angioedema franchise. We look forward to his contributions toward optimizing KALBITOR in hereditary angioedema, advancing KALBITOR in ACE inhibitor-induced angioedema, developing the first-ever laboratory test for non-histamine-mediated angioedemas, and progressing Dyaxas next-generation plasma kallikrein inhibitor toward the clinic.a

aDyax has established KALBITOR as a leader in the acute hereditary angioedema treatment space, and with this, there exists a tremendous opportunity to further expand the Companyas angioedema platform,a stated Dr. Adelman, aI am excited to be working with the Dyax team, as we focus on developing a suite of products designed to identify and appropriately treat the tens of thousands of patients affected by non-histamine-mediated angioedemas.a

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. Dyax's lead product, ecallantide, has been approved under the brand name KALBITOR in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

Dyax is commercializing KALBITOR in the United States independently, and establishing strategic collaborations to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has agreements for regions including Europe, Japan, Russia, the Middle East, Israel, North Africa, Australia, New Zealand, Latin America (excluding Mexico) and the Caribbean. Dyax is also exploring other potential indications for ecallantide, either alone or through collaborations, including drug-induced angioedema.

Ecallantide and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the Licensing and Funded Research Program (LFRP), which has approximately 75 revenue generating licenses and collaborations for therapeutic discovery, as well as for affinity separations, diagnostic imaging, and research reagents. The success of the Company's LFRP portfolio is illustrated by the program's advanced licensee pipeline that includes 18 candidates in clinical development. Of those candidates, four are in Phase 3 clinical trials, four are in Phase 2 and ten are in Phase 1.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit [ www.dyax.com ].

Dyax Disclaimer

This press release contains forward-looking statements, including statements regarding the prospects for therapeutic benefits and treatment advantages of KALBITOR for HAE. Statements that are not historical facts are based on Dyaxas current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the prospects for therapeutic benefits and treatment advantages of KALBITOR for HAE include the risks that: others may develop technologies or products superior to KALBITOR or that are on the market before KALBITOR; KALBITOR may not gain market acceptance; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, marketing, sales and distribution of KALBITOR; and other risk factors described or referred to Item 1A, aRisk Factorsa in Dyaxas most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.

Dyax, the Dyax logo and KALBITOR are registered trademarks and EDEMA3 and EDEMA4 are registered service marks of Dyax Corp. KALBITOR Access is a service mark of Dyax Corp.